Novel CSF biomarkers to discriminate FTLD and its pathological subtypes.

Marta Del Campo MilanDaniela GalimbertiNaura EliasLynn BoonkampYolande A PijnenburgJohn C van SwietenKelly WattsSilvia PaciottiTommaso BeccariWilliam HuCharlotte E Teunissen

Published in: Annals of clinical and translational neurology (2018)

This study identifies CSF protein signatures distinguishing FTLD and the two main pathological subtypes with optimal accuracy (specificity/sensitivity > 80%). Validation of these models may allow appropriate selection of cases for clinical trials targeting the accumulation of Tau or TDP43, thereby increasing their efficiency and facilitating the development of successful therapies.

Keyphrases

clinical trial
genome wide
cerebrospinal fluid
cancer therapy
gene expression
amino acid
small molecule
open label
study protocol